Definition of a genetic network involved in congenital heart disease
This application focuses on transcriptional networks that govern the development of a heart region commonly affected by congenital heart disease (CHD). The major goal is to provide the clinical and basic science research communit...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BFU2015-71519-P
CONTROL TRANSCRIPCIONAL DEL DESARROLLO CARDIACO Y SU IMPACTO...
522K€
Cerrado
PID2019-110155RA-I00
REGULACION TRANSCRIPCIONAL Y SEÑALIZACION CELULAR EN LA DIFE...
109K€
Cerrado
SAF2015-70823-R
ESTUDIO DEL PAPEL DE LAS VARIANTES GENETICAS EN REGIONES NO...
109K€
Cerrado
3-D Cardioid
Decoding enhancer usage and gene expression of human heart d...
190K€
Cerrado
PID2021-126721OB-I00
MECANISMOS MOLECULARES DE LA RELACION GENOTIPO-FENOTIPO EN E...
169K€
Cerrado
Información proyecto CARDIOGENET
Líder del proyecto
FONDAZIONE TELETHON ETS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
This application focuses on transcriptional networks that govern the development of a heart region commonly affected by congenital heart disease (CHD). The major goal is to provide the clinical and basic science research communities with a validated list of interconnected genes required for normal heart development. To achieve this goal, we have recruited 6 European groups of scientists strongly committed to CHD research. The participants bring to the consortium significant resources and credible synergy. The entry point for the interrogation and perturbation of cardiogenic gene networks will be the transcription factor Tbx1, the major gene for 22q11.2 deletion syndrome, a common genetic cause of CHD. The project has three specific aims: 1) To define the roles and interactions of T-box transcription factors in cardiac outflow tract (OFT) development. Our hypothesis is that a critical balance of Tbx1, 2, and 3 is required to regulate homeostasis of a specific population of cardiac progenitors and their interactions with non-cardiogenic cells. 2) To define gene networks perturbed in OFT developmental defects. Innovative approaches will identify the transcriptional targets and protein interactors of Tbx1. Candidate genes will be validated in vitro and in vivo using mouse and zebrafish models. In addition, we will perform extensive transcriptome analyses using biopsy material from CHD patients in order to integrate animal and patient data. 3) To integrate gene expression, cell lineage distribution and phenotype data. Normal heart morphology is achieved through a concerted gene expression program and the integration of molecular signals and tissue interactions. Aided by 3-dimensional reconstruction of gene expression patterns and phenotypic information, we will integrate different types of data to develop models of CHD pathogenesis. Teamwork will be enhanced by shared technologies that provide homogeneity and comparability of data between the participating labs.